Home・Listă Acțiuni・AnaptysBio Inc

AnaptysBio Inc

Închisă

SectorSănătate

56.23 3.14

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

54.52

Maxim

57.16

Indicatori cheie
By Trading Economics
Venit	-102M -53M
Vânzări	-83M 26M
EPS	-1.843
Marjă de profit	-206.934
Angajați	104
EBITDA	-99M -31M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+42.5% upside

Dividende
By Acuity
Următoarele câștiguri	11 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-388M 1.6B
Deschiderea anterioară	53.09
Închiderea anterioară	56.23

Sentimentul știrilor

By Acuity

50%

151 / 340 Clasament în Healthcare

AnaptysBio Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

7 aug. 2026, 19:26 UTC

AnaptysBio Inc. shares are trading higher today, continuing a trend since Thursday's close, despite notable volatility during the session.

5 aug. 2026, 19:36 UTC

AnaptysBio Inc. shares are lower in Wednesday's session, having declined from earlier highs amid routine market fluctuations and trading near the lower end of its recent range.

3 aug. 2026, 20:06 UTC

AnaptysBio Inc shares are higher today, recovering from earlier losses amid a broader market rally in the S&P 500 and Nasdaq 100 indices.

31 iul. 2026, 20:06 UTC

AnaptysBio Inc shares are lower, reflecting broader market weakness amid rising Treasury yields and crude oil prices, with no specific company news identified.

30 iul. 2026, 23:36 UTC

AnaptysBio Inc. shares declined after-market, reflecting ongoing weakness amid broader market volatility and the Federal Reserve's interest rate decisions.

29 iul. 2026, 19:56 UTC

Macro Event

AnaptysBio Inc shares are higher, recovering from an earlier dip, amid market volatility following the Federal Reserve's decision to maintain interest rates steady.

28 iul. 2026, 23:16 UTC

AnaptysBio Inc shares are higher in after-market trading, recovering from earlier lows. No specific news was identified to explain the movement.

24 iul. 2026, 19:16 UTC

AnaptysBio Inc shares are lower today, reflecting a decline since Thursday. Broader market sentiment is affected by recent volatility in oil prices.

23 iul. 2026, 09:16 UTC

AnaptysBio Inc is trading lower in pre-market hours amid broader market pressures from disappointing earnings reports and rising geopolitical tensions.

22 iul. 2026, 22:16 UTC

AnaptysBio Inc shares are higher in after-market hours, trading above Wednesday's close amid broader market concerns over rising crude oil prices and U.S.-Iran tensions.

21 iul. 2026, 20:12 UTC

AnaptysBio Inc. shares are lower in after-market trading, continuing a downward trend and positioning the stock below its 20-day moving average.

20 iul. 2026, 23:01 UTC

AnaptysBio Inc. shares are higher in after-market trading, reflecting routine activity. The stock remains below its 20-day moving average.

Comparație

Modificare preț

AnaptysBio Inc Așteptări

Obiectiv de preț

By TipRanks

42.5% sus

Prognoză pe 12 luni

Medie 80.67 USD 42.5%

Maxim 95 USD

Minim 70 USD

În baza a 7 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruAnaptysBio Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

7 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 7 analiști care au acordat evaluări ale acțiunilor AnaptysBio Inc - Dist în ultimele 3 luni.

Sentiment

By Acuity

151 / 340 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre AnaptysBio Inc

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.